We describe a new two-step culture method for mass production in vitro of erythroid cells from either CD34(+) (10(5) cells/mL) or light-density (10(6) cells/mL) cells purified from the blood of normal donors and thalassemic patients. The method includes (i) culture of the cells in the presence of dexamethasone and estradiol(10(-6) M each) and (ii) the growth factors SCF (50 ng/mL), IL-3 (1 ng/mL), and EPO (1 U/mL). In their proliferative phase, these cultures generated congruent to 1-2 x 10(7) erythroblasts for each milliliter of blood collected from normal donors or thalassemic patients. They were composed mostly (90%) of CD45(low)/glycophorin (GPA)(neg)/CD71(low) cells at day 7, 50 - 60% of which became CD45(neg)/GPA(+)/CD71(high) by days 15-20. However, when cells from days 7 to 12 of the proliferative phase were transferred in differentiation medium containing EPO and insulin, they progressed to mature erythroblasts (>90% benzidine(pos) and CD45(neg)/GPA(+)/CD71(medium)) in 4 days. Because of the high number of erythroid cells that are generated from modest volumes of blood, this method will prove useful in donor-specific studies of erythroid differentiation.
In Vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients
DI PIETRO, Roberta;DI GIACOMO, Viviana;DI BALDASSARRE, Angela;
2002-01-01
Abstract
We describe a new two-step culture method for mass production in vitro of erythroid cells from either CD34(+) (10(5) cells/mL) or light-density (10(6) cells/mL) cells purified from the blood of normal donors and thalassemic patients. The method includes (i) culture of the cells in the presence of dexamethasone and estradiol(10(-6) M each) and (ii) the growth factors SCF (50 ng/mL), IL-3 (1 ng/mL), and EPO (1 U/mL). In their proliferative phase, these cultures generated congruent to 1-2 x 10(7) erythroblasts for each milliliter of blood collected from normal donors or thalassemic patients. They were composed mostly (90%) of CD45(low)/glycophorin (GPA)(neg)/CD71(low) cells at day 7, 50 - 60% of which became CD45(neg)/GPA(+)/CD71(high) by days 15-20. However, when cells from days 7 to 12 of the proliferative phase were transferred in differentiation medium containing EPO and insulin, they progressed to mature erythroblasts (>90% benzidine(pos) and CD45(neg)/GPA(+)/CD71(medium)) in 4 days. Because of the high number of erythroid cells that are generated from modest volumes of blood, this method will prove useful in donor-specific studies of erythroid differentiation.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S1079979602905024-main.pdf
accesso aperto
Tipologia:
Documento in Pre-print
Dimensione
182.08 kB
Formato
Adobe PDF
|
182.08 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.